This is more research out of the Mayo Rochester Epidemiology Project, looking at 461 people in Olmsted County, MN who were diagnosed with a synucleinopathy with parkinsonism between 1991 and 2010. Synucleinopathies included were Parkinson’s Disease (PD), dementia with Lewy bodies (DLB), Parkinson’s Disease Dementia (PDD), and multiple system atrophy-parkinsonism (MSA-p). These were matched with county residents without parkinsonism.
Those with MSA-p died 6 years earlier than others with synucleinopathies, and those with DLB (4 years) or PDD (3.5 years) had a shorter lifespan than normal controls. And having PD took one year off a person’s lifespan.
Here’s a MedPage Today article about the research:
Higher Death Risk With All Synucleinopathies
Lowest with Parkinson’s disease, highest for multiple system atrophy with parkinsonism
by Kristin Jenkins
Contributing Writer, MedPage Today
May 15, 2017
(You can view the article once without signing up. Signing up is free.)
Updated in July 2017:
The article described above has this citation:
Savica R, Grossardt BR, Bower JH, et al. Survival and causes of death among people with clinically diagnosed synucleinopathies with parkinsonism: a population-based study. [Published online May 15, 2017]. JAMA Neurol. Accessed June 8, 2017.
Recently, Clinical Neurology News published these five questions to test your knowledge of outcomes in synucleinopathies — dementia with Lewy bodies, Parkinson’s disease dementia, multiple system atrophy, and Parkinson’s disease:
Most of the questions are about DLB, PDD, and MSA. The questions are based on the JAMA Neurology article.